Evidence map›Paper›PMID 41747748›Full record

ArticleThe lancet. HIV2026

Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.

Thumbi Ndung'u, Krista L Dong, Donn J Colby, Steven G Deeks, Mark F Cotton, Karine Dubé, Philip J Goulder, Boris Julg, Moses Nsubuga, Gbolahan Ajibola and 26 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in The lancet. HIV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines.Journal of the International AIDS Society · 2026
    Article
  4. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa; Division of Infection and Immunity, University College London, London, UK; Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Electronic address: thumbi.ndungu@ahri.org.
Krista L DongRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Cambridge, MA, USA; Infectious Diseases Division, Massachusetts General Hospital, Boston, MA, USA.
Donn J ColbyUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Steven G DeeksDivision of HIV, Infectious Diseases & Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Mark F CottonFamily Center for Clinical Research with Ubuntu, Department of Paediatrics and Child Health, Tygerberg Academic Hospital, Stellenbosch University, Cape Town, South Africa.
Karine DubéDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California, San Diego, San Diego, CA, USA.
Philip J GoulderAfrica Health Research Institute, Durban, South Africa; Division of Infection and Immunity, University College London, London, UK; Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Department of Paediatrics, Oxford University, Oxford, UK.
Boris JulgRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Cambridge, MA, USA.
Moses NsubugaJoint Adherent Brothers and Sisters Against AIDS, Kampala, Uganda.
Gbolahan AjibolaBotswana Harvard Health Partnership, Gaborone, Botswana.
Katharine J BarDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nomonde BenguUmkhuseli Innovation and Research Management, Durban, South Africa.
Mutsa Bwakura-DangarembiziDepartment of Paediatrics and Child Health, University of Zimbabwe, Harare, Zimbabwe.
Marina CaskeyLaboratory of Molecular Immunology, Rockefeller University, New York, NY, USA.
Gabriela CromhoutDepartment of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa.
Adeodata R KekitiinwaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
William KilembeCenter for Family Health Research, Lusaka, Zambia.
Louise KuhnGertrude H Sergievsky Center, Vagelos College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Udom LikhitwonnawutThailand National CAB, Chiang Mai, Thailand.
Nyaradzo M MgodiUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Deborah PersaudDepartment of Pediatrics, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael J PelusoDivision of HIV, Infectious Diseases & Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Thomas A RasmussenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Infectious Diseases, Aarhus University, Aarhus, Denmark.
Matthew RomoUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Carlo SacdalanSEARCH Research Foundation, Bangkok, Thailand; Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Wadzanai SamanekaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Roger ShapiroDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA.
Ole S SøgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Infectious Diseases, Aarhus University, Aarhus, Denmark.
Gareth Tudor-WilliamsDepartment of Infectious Diseases and Centre for Paediatrics and Child Health, Imperial College London, London, UK.
Charity WambuiMoi University Clinical Research Centre, Eldoret, Kenya.
Randall TresslerDivision of AIDS, National Institute of Allergy and Infectious Diseases; National Institutes of Health, Bethesda, MD, USA.
Sharon R LewinDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Trevor A CrowellUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Victoria O KasprowiczAfrica Health Research Institute, Durban, South Africa; Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Lydie TrautmannUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. Electronic address: ltrautmann@Global-ID.org.
2nd ATI Consensus Workshop

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
NIAID NIH HHS UM1 AI164566
6 · The paper itself

Abstract

Analytical treatment interruption (ATI) is an important tool to evaluate interventions designed to achieve HIV eradication or long-term control without antiretroviral therapy. We convened a stakeholder workshop to update the published recommendations for the conduct of ATI studies. Important changes to the recommendations include more lenient entry criteria on CD4 count, CD4 nadir, and past medical history, and allowance for greater variation based on regional standards. As the mechanism of potential HIV remission might rely on immune control, the criteria for antiretroviral therapy resumption now allow for longer periods of viraemia at higher levels to stimulate a more robust immune response. Greater emphasis is placed on the importance of psychosocial monitoring and support, the prevention of HIV transmission to partners during ATI, and the integration of sociobehavioural research into ATI studies. Recommendations for the conduct of paediatric and adolescent ATI trials, absent from previous guidelines, are now included. These recommendations, based on current available data, expert opinion, and community consultation, aim to help steer the safe and ethical implementation of the next generation of ATI trials as we continue the search for an HIV cure.

Indexed as

Anti-HIV AgentsClinical Trials as TopicHIV InfectionsTreatment InterruptionCD4 Lymphocyte CountHumansAnti-HIV Agents

Identifiers

PMID41747748
PMCPMC13316505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.